Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma

Patients with ROS1-rearranged non-small cell lung cancer (NSCLC) inevitably relapse after first-line targeted therapy with tyrosine kinase inhibitors. Efficacy of checkpoint inhibitor-based therapy on ROS1-positive NSCLC in second-line setting and change of immune factors during treatment are rarely...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Dongsheng, Qian, Juanjuan, Chen, Zhipeng, Zhang, Bin, Chen, Peng, Zhang, Lei, Li, Jingjing, Zhang, Henghui, Wang, Changli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871696/
https://www.ncbi.nlm.nih.gov/pubmed/33558279
http://dx.doi.org/10.1136/jitc-2020-001967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871696/
https://www.ncbi.nlm.nih.gov/pubmed/33558279
http://dx.doi.org/10.1136/jitc-2020-001967

Ejemplares similares